Vitrolife
eröffnet am 26.08.16 12:33:38 von
neuester Beitrag 21.04.23 12:23:57 von
neuester Beitrag 21.04.23 12:23:57 von
Beiträge: 31
ID: 1.237.443
ID: 1.237.443
Aufrufe heute: 0
Gesamt: 4.493
Gesamt: 4.493
Aktive User: 0
ISIN: SE0011205202 · WKN: A2JLT3
13,955
EUR
+2,80 %
+0,380 EUR
Letzter Kurs 22:35:23 Lang & Schwarz
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,9000 | +59,66 | |
| 0,5922 | +44,44 | |
| 6,7820 | +42,78 | |
| 11,790 | +42,05 | |
| 0,7000 | +36,69 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 10,110 | -13,44 | |
| 4,3600 | -13,49 | |
| 1,6900 | -14,50 | |
| 2,8150 | -15,21 | |
| 2,1200 | -21,77 |
Beitrag zu dieser Diskussion schreiben
Feedback
Geschäft weiterhin positiv in Q1/2023, auch wenn es die heutige Kursentwicklung nicht vermuten lässt:
https://view.news.eu.nasdaq.com/view?id=bbe0819f55b9f1afa413…
so long
linkshaender
https://view.news.eu.nasdaq.com/view?id=bbe0819f55b9f1afa413…
so long
linkshaender
Hallo allerseits,
ist hier außer mir noch jemand investiert?
Viele Grüße,
Fel
ist hier außer mir noch jemand investiert?
Viele Grüße,
Fel
Antwort auf Beitrag Nr.: 68.780.975 von Quaglia am 15.07.21 08:33:51
nicht billig, aber sehr interessantes Geschäftsfeld.
so long
linkshaender
Wieder mal schöne Entwicklung
https://view.news.eu.nasdaq.com/view?id=b2a6dde61c1cc12b35e2…nicht billig, aber sehr interessantes Geschäftsfeld.
so long
linkshaender
ja, ich bin noch da und es gibt mal wieder schöne Zahlen:
https://view.news.eu.nasdaq.com/view?id=be291ec14077f466fd1e…
https://view.news.eu.nasdaq.com/view?id=be291ec14077f466fd1e…
Guten Morgen! Ist hier noch jemand? Ich ärgere mich, erst jetzt von Vitrolife gehört zu haben. Habe mir nun aber eine kleine Position zugelegt und freue lich auf die kommenden Jahre.
Trading Spotlight
Antwort auf Beitrag Nr.: 61.010.645 von linkshaender am 12.07.19 10:40:00.. und nochmal excellente Werte:
https://news.cision.com/vitrolife-ab--publ-/r/interim-report…
Ich hoffe, auf eine Chance zum Aufstocken.
https://news.cision.com/vitrolife-ab--publ-/r/interim-report…
Ich hoffe, auf eine Chance zum Aufstocken.
Vitrolife acquires the business of UK distributor Parallabs
Vitrolife has today acquired the business of Parallabs Ltd, its distributor in UK and Ireland for EmbryoScope time-lapse systems, and thereby strengthens its presence in UK and Ireland.Parallabs Ltd has been the Vitrolife UK and Ireland distributor for EmbryoScope time-lapse systems since 2011 and has achieved a high penetration for time-lapse in the market. “The acquisition strengthens Vitrolife in the UK and Ireland by getting access to a wealth of experience from Parallabs, as well as being able to offer customers the complete Vitrolife portfolio from a single sales channel”; says Thomas Axelsson, CEO of Vitrolife AB. “We are delighted to join Vitrolife and together build on the presence and reputation of both companies”; says Phil Branston, majority owner and founder of Parallabs Ltd.
The initial purchase price amounted to GBP 1.9 million. The purchase price was paid in cash and was financed by available cash balances. In addition to the initial purchase price, additional purchase price of GBP 0.5 million may be paid in relation to sales targets. The transaction is expected to be accretive to group revenue of approximately GBP 1 million for a twelve-month period and marginally accretive to EBITDA per share.
Vitrolife acquires artificial intelligence technology for embryo assessment
Vitrolife has acquired rights to a technology for assessing embryos based on time-lapse videos using artificial intelligence (“AI”) and entered into collaboration agreements to further develop the technology.
Vitrolife has entered into transfer and collaboration agreements regarding a technology for assessing embryos with Virtus Health, a leading IVF clinic group based in Australia and Harrison.AI, a technology company specialising in the development of AI software in healthcare applications based in Australia.
Using time-lapse videos during in vitro fertilisation (IVF), and before embryo transfer, the technology can predict the likelihood of an embryo to lead to a viable pregnancy. The AI technology will support elective single embryo transfer and is anticipated to shorten the time to pregnancy by helping Fertility & IVF practitioners to rank the most viable embryos for selection and transfer.
The agreements comprise two main components:
• Transfer of intellectual property and patent applications relating to the technology from the current owners responsible for the development, Virtus Health and Harrison.AI, and
• Collaboration agreements between the parties for an initial period of three years to ensure further development of the technology in the time-lapse incubator application.
Vitrolife is the market leader of time-lapse systems for use in assisted reproduction, providing undisturbed culture and improved selection of embryos. “We are delighted to announce the collaboration with Virtus Health and Harrison.AI to develop and market a state-of-the-art AI technology for the EmbryoScope time-lapse systems”, says Thomas Axelsson, CEO of Vitrolife.
The initial purchase price related to the transfer amounted to USD 6 million. The purchase price was paid in cash and was financed by available cash balances. In addition to the initial purchase price, additional purchase price of USD 2 million may be paid in relation to product development targets. The transaction is expected to impact EBITDA per share marginally negatively during 2019 and positively as from 2020, when the technology is expected to be commercially launched.
April 10, 2019
Vitrolife has acquired rights to a technology for assessing embryos based on time-lapse videos using artificial intelligence (“AI”) and entered into collaboration agreements to further develop the technology.
Vitrolife has entered into transfer and collaboration agreements regarding a technology for assessing embryos with Virtus Health, a leading IVF clinic group based in Australia and Harrison.AI, a technology company specialising in the development of AI software in healthcare applications based in Australia.
Using time-lapse videos during in vitro fertilisation (IVF), and before embryo transfer, the technology can predict the likelihood of an embryo to lead to a viable pregnancy. The AI technology will support elective single embryo transfer and is anticipated to shorten the time to pregnancy by helping Fertility & IVF practitioners to rank the most viable embryos for selection and transfer.
The agreements comprise two main components:
• Transfer of intellectual property and patent applications relating to the technology from the current owners responsible for the development, Virtus Health and Harrison.AI, and
• Collaboration agreements between the parties for an initial period of three years to ensure further development of the technology in the time-lapse incubator application.
Vitrolife is the market leader of time-lapse systems for use in assisted reproduction, providing undisturbed culture and improved selection of embryos. “We are delighted to announce the collaboration with Virtus Health and Harrison.AI to develop and market a state-of-the-art AI technology for the EmbryoScope time-lapse systems”, says Thomas Axelsson, CEO of Vitrolife.
The initial purchase price related to the transfer amounted to USD 6 million. The purchase price was paid in cash and was financed by available cash balances. In addition to the initial purchase price, additional purchase price of USD 2 million may be paid in relation to product development targets. The transaction is expected to impact EBITDA per share marginally negatively during 2019 and positively as from 2020, when the technology is expected to be commercially launched.
April 10, 2019
Durchsuchen
